Developer docs
API playgroundTry for free, no card

Search company profiles

CoMind

Full company profile

uuid0006dur

Namestring
CoMind
Legal namestring
CoMind Technologies Limited
Websiteurl
comind.io
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CoMind Technologies Limited is a London-based neurotechnology company developing non-invasive optical sensors for continuous monitoring of cerebral blood flow, intracranial pressure, and cerebral autoregulation. Its technology is built on a proprietary time-of-flight resolved interferometric sensing platform operating at 1064nm, derived from LiDAR-class photonics and adapted into a clinical-grade wearable intended to replace invasive intracranial bolts currently used in neurocritical care. The lead commercial product, the CoMind One, is planned for launch in 2027; the CoMind R1 serves as a research prototype supporting early clinical and academic engagement.

CoMind is pre-revenue and pre-FDA, with US clinical trials underway to support regulatory clearance. The company's go-to-market targets hospital ICUs, cardiac and vascular surgery units, and traumatic brain injury (TBI) settings where invasive neuromonitoring is the standard of care. To date, CoMind has raised approximately $102.5M across multiple rounds, including a $27M round in 2023 and a $60M Series A in October 2025 led by Plural. A manufacturing partnership with Benchmark supports production scale-up, and peer-reviewed validation has appeared in Neurophotonics (March 2026). The company is led by Chairman Frank Fischer (appointed March 2025) and operates with 51–100 employees, with the team weighted toward R&D, clinical, and regulatory functions rather than a deployed commercial salesforce.

The business model is a regulated medical-device sale into hospital systems, with revenue per device and recurring disposable or service economics typical of critical-care monitoring platforms, though no pricing, ASP, or contract structure has been disclosed. Strategic intent, as evidenced by the Series A use of funds, the US clinical program, and the Benchmark manufacturing partnership, is to clear FDA, launch the CoMind One in 2027, and establish CoMind as the first non-invasive clinical-grade alternative to invasive cerebral monitoring.

Short descriptiontext

CoMind Technologies Limited is a London-based neurotechnology company building non-invasive optical sensors that monitor cerebral blood flow, intracranial pressure, and autoregulation, targeting hospital neurocritical care, cardiac/vascular surgery, and TBI markets ahead of a planned 2027 launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive neuromonitoring, brain monitoring devices, cerebral blood flow monitoring, intracranial pressure monitoring, optical sensing technology
Industry2 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Neuromonitoring Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

CoMind One is a medical device that will be sold to healthcare providers (hospitals, ICUs). The company is preparing for commercial deployment and manufacturing scale-up.

bench.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CoMind develops a non-invasive brain monitoring system (CoMind One) that uses time-of-flight resolved interferometric optical sensing with safe 1064nm infrared laser light to measure cerebral blood flow, intracranial pressure, and cerebral autoregulation. The device uses a small adhesive sensor placed on the patient's forehead, eliminating the need for invasive intracranial bolts that carry complication rates of up to 15 percent. The system delivers continuous, multi-parameter neurophysiological monitoring at the bedside for critical care, cardiac and vascular surgery, and traumatic brain injury management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Traditional intracranial bolts lead to complications in up to 15 percent of cases
+2 more records
Product overview1 text field

CoMind is developing a non-invasive brain monitoring system centered around CoMind One, their primary clinical product designed for bedside monitoring of cerebral blood flow, intracranial pressure, and autoregulation using advanced optical sensing technology. The technology uses safe levels of laser light transmitted through head tissues with interferometric detection to provide depth-resolved sensitivity to blood flow dynamics. CoMind R1 serves as their research prototype that demonstrated the scientific foundation and technical performance required for clinical translation. The company aims to make brain tracking as simple and accessible as a pulse check, replacing the need for invasive intracranial procedures.

Product and service2 records
1CoMind One
CategoryNeuromonitoring Medical Device
Description

A non-invasive brain monitoring system designed for healthcare providers, providing real-time insight into cerebral perfusion, autoregulation, and intracranial pressure using advanced infrared light technology. Built around a simple adhesive forehead sensor, it delivers continuous brain physiology signals to clinicians across critical care settings including cardiac and vascular surgery, intensive care, and traumatic brain injury management.

2CoMind R1
CategoryResearch Prototype / Technology Demonstrator
Description

A time-resolved interferometric optical neuromonitoring research prototype integrating a high-power linearly-swept 1064 nm laser with multimode fibre collection, parallelised detection, and real-time signal processing. Achieves an instrument response function width of 120 picoseconds with no significant drift over 24 hours of continuous operation, and has been used in studies of 25 healthy adults producing high-quality pulsatile cerebral blood flow waveforms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Benchmark
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

CoMind has partnered with Benchmark as its development and manufacturing partner to create a non-invasive brain monitoring device. Benchmark provides manufacturing expertise to support the product development and eventual commercialization.

bench.com
2Clinical Advisory Board
Strategic tierCoreTypeOthers
comind.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic's INVOS (In-Vivo Optical Spectroscopy) cerebral oximeter is a market-leading NIRS device used during cardiac surgery and in the ICU. As a diversified medical device incumbent with deep relationships across US hospital systems, it represents the entrenched incumbent CoMind must displace.

TypeDirect peer
Description

Masimo's O3 Regional Oximetry is an FDA-cleared NIRS-based cerebral oximeter used in ICU and perioperative settings. It is the closest direct competitor to CoMind One, addressing the same clinical need (non-invasive cerebral oxygenation) with an established hospital installed base.

3Nihon Kohden
TypeBroad incumbent
Description

Nihon Kohden is a global leader in patient monitoring and neurological diagnostics (EEG, cerebral oximetry, neuromonitoring). As a diversified incumbent with strong hospital relationships in both US and Europe, it represents the integrated monitoring platform CoMind must integrate with or compete against.

TypeBroad incumbent
Description

Natus provides a broad portfolio of neurodiagnostic and neurocritical care devices including EEG, ICP monitors, and cerebral oximetry modules. As an established incumbent across multiple neurology/neurocritical care modalities, it competes for the same hospital budget.

TypeDirect peer
Description

Ornim's CerOx device uses ultrasound-tagged NIRS (UT-NIRS) to non-invasively measure cerebral blood flow and oxygenation. As a startup focused exclusively on cerebral oximetry with novel optical approaches, it parallels CoMind's strategy of bringing next-generation physics to non-invasive brain monitoring.

TypeBroad incumbent
Description

Edwards' FORE-SIGHT cerebral oximeter is another FDA-cleared NIRS cerebral oxygenation monitor used in cardiac surgery and critical care. As part of Edwards' broader hemodynamic monitoring portfolio, it benefits from cross-selling into the same OR and ICU channels CoMind targets.

TypeEmerging player
Description

Hyperfine developed the Swoop portable MRI for point-of-care brain imaging, addressing the same unmet need (better, more accessible brain assessment) in critical care. It is a comparable emerging player in novel bedside neurotechnology, though using a different modality (MRI vs. optics).

TypeDirect peer
Description

Nonin Medical manufactures NIRS-based cerebral oximeters (Equanox) for use in operating rooms and ICUs. It is a focused competitor in non-invasive cerebral monitoring, similar in product positioning to CoMind but lacking CoMind's depth-resolved ToF architecture.

TypeDirect peer
Description

Moberg provides multimodal brain monitoring solutions for the ICU, including EEG and cerebral oximetry data aggregation. It competes with CoMind in the same ICU brain-monitoring niche and addresses similar clinical pain points around integrated bedside brain data.

TypeDirect peer
Description

NovaSignal develops the NovaGuide 2, an ultrasound-based system for non-invasive, real-time cerebral blood flow assessment. It competes with CoMind in the same clinical use case (non-invasive cerebral hemodynamics) using a different underlying physics modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CoMind

Neuromonitoring Medical Devicescomind.io

CoMind Technologies Limited is a London-based neurotechnology company building non-invasive optical sensors that monitor cerebral blood flow, intracranial pressure, and autoregulation, targeting hospital neurocritical care, cardiac/vascular surgery, and TBI markets ahead of a planned 2027 launch.

What CoMind does

CoMind Technologies Limited is a London-based neurotechnology company developing non-invasive optical sensors for continuous monitoring of cerebral blood flow, intracranial pressure, and cerebral autoregulation. Its technology is built on a proprietary time-of-flight resolved interferometric sensing platform operating at 1064nm, derived from LiDAR-class photonics and adapted into a clinical-grade wearable intended to replace invasive intracranial bolts currently used in neurocritical care. The lead commercial product, the CoMind One, is planned for launch in 2027; the CoMind R1 serves as a research prototype supporting early clinical and academic engagement.

CoMind is pre-revenue and pre-FDA, with US clinical trials underway to support regulatory clearance. The company's go-to-market targets hospital ICUs, cardiac and vascular surgery units, and traumatic brain injury (TBI) settings where invasive neuromonitoring is the standard of care. To date, CoMind has raised approximately $102.5M across multiple rounds, including a $27M round in 2023 and a $60M Series A in October 2025 led by Plural. A manufacturing partnership with Benchmark supports production scale-up, and peer-reviewed validation has appeared in Neurophotonics (March 2026). The company is led by Chairman Frank Fischer (appointed March 2025) and operates with 51–100 employees, with the team weighted toward R&D, clinical, and regulatory functions rather than a deployed commercial salesforce.

The business model is a regulated medical-device sale into hospital systems, with revenue per device and recurring disposable or service economics typical of critical-care monitoring platforms, though no pricing, ASP, or contract structure has been disclosed. Strategic intent, as evidenced by the Series A use of funds, the US clinical program, and the Benchmark manufacturing partnership, is to clear FDA, launch the CoMind One in 2027, and establish CoMind as the first non-invasive clinical-grade alternative to invasive cerebral monitoring.

CoMind firmographics

Firmographics
Name
CoMind
Legal name
CoMind Technologies Limited
Website
https://comind.io
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
CoMind Technologies Limited is a London-based neurotechnology company building non-invasive optical sensors that monitor cerebral blood flow, intracranial pressure, and autoregulation, targeting hospital neurocritical care, cardiac/vascular surgery, and TBI markets ahead of a planned 2027 launch.
Ownership category
akta.pro rank

CoMind industry classification

Industry
Product category
Neuromonitoring Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Non-invasive neuromonitoring
  • Brain monitoring devices
  • Cerebral blood flow monitoring
  • Intracranial pressure monitoring
  • Optical sensing technology

Where CoMind is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

CoMind business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: CoMind One is a medical device that will be sold to healthcare providers (hospitals, ICUs). The company is preparing for commercial deployment and manufacturing scale-up.

Go-to-market motion2 records

Marketing channels4 records

CoMind product offering

Product offering

Core offering

CoMind develops a non-invasive brain monitoring system (CoMind One) that uses time-of-flight resolved interferometric optical sensing with safe 1064nm infrared laser light to measure cerebral blood flow, intracranial pressure, and cerebral autoregulation. The device uses a small adhesive sensor placed on the patient's forehead, eliminating the need for invasive intracranial bolts that carry complication rates of up to 15 percent. The system delivers continuous, multi-parameter neurophysiological monitoring at the bedside for critical care, cardiac and vascular surgery, and traumatic brain injury management.

Product overview

CoMind is developing a non-invasive brain monitoring system centered around CoMind One, their primary clinical product designed for bedside monitoring of cerebral blood flow, intracranial pressure, and autoregulation using advanced optical sensing technology. The technology uses safe levels of laser light transmitted through head tissues with interferometric detection to provide depth-resolved sensitivity to blood flow dynamics. CoMind R1 serves as their research prototype that demonstrated the scientific foundation and technical performance required for clinical translation. The company aims to make brain tracking as simple and accessible as a pulse check, replacing the need for invasive intracranial procedures.

Differentiator

Problem solved

Functional benefit

Products and services

  • CoMind One A non-invasive brain monitoring system designed for healthcare providers, providing real-time insight into cerebral perfusion, autoregulation, and intracranial pressure using advanced infrared light technology. Built around a simple adhesive forehead sensor, it delivers continuous brain physiology signals to clinicians across critical care settings including cardiac and vascular surgery, intensive care, and traumatic brain injury management.
  • CoMind R1 A time-resolved interferometric optical neuromonitoring research prototype integrating a high-power linearly-swept 1064 nm laser with multimode fibre collection, parallelised detection, and real-time signal processing. Achieves an instrument response function width of 120 picoseconds with no significant drift over 24 hours of continuous operation, and has been used in studies of 25 healthy adults producing high-quality pulsatile cerebral blood flow waveforms.

Quantifiable outcome

  • Traditional intracranial bolts lead to complications in up to 15 percent of cases
  • +2 more outcomes

Companies that use CoMind

Customer profile

Segments3 records

Ideal customer profiles3 records

CoMind technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

CoMind partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BenchmarkcoreStrategic or Co-development Partner · 24 October 2025CoMind has partnered with Benchmark as its development and manufacturing partner to create a non-invasive brain monitoring device. Benchmark provides manufacturing expertise to support the product development and eventual commercialization.
  • Clinical Advisory BoardcoreOthers

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

CoMind competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic's INVOS (In-Vivo Optical Spectroscopy) cerebral oximeter is a market-leading NIRS device used during cardiac surgery and in the ICU. As a diversified medical device incumbent with deep relationships across US hospital systems, it represents the entrenched incumbent CoMind must displace.
  • Nihon Kohden: Nihon Kohden is a global leader in patient monitoring and neurological diagnostics (EEG, cerebral oximetry, neuromonitoring). As a diversified incumbent with strong hospital relationships in both US and Europe, it represents the integrated monitoring platform CoMind must integrate with or compete against.
  • Natus Medical: Natus provides a broad portfolio of neurodiagnostic and neurocritical care devices including EEG, ICP monitors, and cerebral oximetry modules. As an established incumbent across multiple neurology/neurocritical care modalities, it competes for the same hospital budget.
  • Edwards Lifesciences: Edwards' FORE-SIGHT cerebral oximeter is another FDA-cleared NIRS cerebral oxygenation monitor used in cardiac surgery and critical care. As part of Edwards' broader hemodynamic monitoring portfolio, it benefits from cross-selling into the same OR and ICU channels CoMind targets.

Direct peers

  • Masimo: Masimo's O3 Regional Oximetry is an FDA-cleared NIRS-based cerebral oximeter used in ICU and perioperative settings. It is the closest direct competitor to CoMind One, addressing the same clinical need (non-invasive cerebral oxygenation) with an established hospital installed base.
  • Ornim Medical: Ornim's CerOx device uses ultrasound-tagged NIRS (UT-NIRS) to non-invasively measure cerebral blood flow and oxygenation. As a startup focused exclusively on cerebral oximetry with novel optical approaches, it parallels CoMind's strategy of bringing next-generation physics to non-invasive brain monitoring.
  • Nonin Medical: Nonin Medical manufactures NIRS-based cerebral oximeters (Equanox) for use in operating rooms and ICUs. It is a focused competitor in non-invasive cerebral monitoring, similar in product positioning to CoMind but lacking CoMind's depth-resolved ToF architecture.
  • Moberg ICU Solutions: Moberg provides multimodal brain monitoring solutions for the ICU, including EEG and cerebral oximetry data aggregation. It competes with CoMind in the same ICU brain-monitoring niche and addresses similar clinical pain points around integrated bedside brain data.
  • NovaSignal: NovaSignal develops the NovaGuide 2, an ultrasound-based system for non-invasive, real-time cerebral blood flow assessment. It competes with CoMind in the same clinical use case (non-invasive cerebral hemodynamics) using a different underlying physics modality.

Emerging players

  • Hyperfine: Hyperfine developed the Swoop portable MRI for point-of-care brain imaging, addressing the same unmet need (better, more accessible brain assessment) in critical care. It is a comparable emerging player in novel bedside neurotechnology, though using a different modality (MRI vs. optics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CoMind social profiles

Digital presence

CoMind financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CoMind leadership team

Management profile

Number of profiles

Profiles8 records

CoMind funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CoMind M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoMind

What does CoMind do?

CoMind develops a non-invasive brain monitoring system (CoMind One) that uses time-of-flight resolved interferometric optical sensing with safe 1064nm infrared laser light to measure cerebral blood flow, intracranial pressure, and cerebral autoregulation. The device uses a small adhesive sensor placed on the patient's forehead, eliminating the need for invasive intracranial bolts that carry complication rates of up to 15 percent. The system delivers continuous, multi-parameter neurophysiological monitoring at the bedside for critical care, cardiac and vascular surgery, and traumatic brain injury management.

Is CoMind a public or private company?

CoMind is a private company. It is classified as venture growth investor backed and is currently operating.

When was CoMind founded?

CoMind was founded in 2018. It employs 51 to 100 people.

Where is CoMind based?

CoMind is headquartered in London, United Kingdom, in the Europe region.

How does CoMind make money?

One revenue line is on record: medical Device Sales.

Who are CoMind's main competitors?

Broad incumbents on record are Medtronic, Nihon Kohden, Natus Medical and Edwards Lifesciences. Direct peers are Masimo, Ornim Medical, Nonin Medical, Moberg ICU Solutions and NovaSignal. Hyperfine is listed as an emerging player.

Does CoMind have an API?

No public API is recorded for CoMind.

What industry is CoMind in?

CoMind's product category is Neuromonitoring Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessinsiderJames Dacombe, el joven de 25 años que abandonó la universidad y se ha convertido en el multimillonario más joven de EuropaJames Dacombe, 25, became Europe's youngest self-made multimillionaire after founding Olix, a chip company that tripled to $3.3 billion in six months. He holds a 12% stake in CoMind, which raised $102.5 million in August 2025. His photonic chips are expected to launch in 2027.The Times of IndiaJames Dacombe: The Gen Z founder who left school at 17 and built a $3.3 billion AI chip company, becoming Europe’s youngest self-made billionaire at 25James Dacombe, a 25-year-old British entrepreneur, became Europe’s youngest self-made billionaire following his AI chip company Olix's $312 million funding round at a $3.3 billion valuation in August 2026. Dacombe holds approximately a 30% stake in Olix, which he founded after previously launching the brain-technology firm CoMind. This financial milestone places him among a small group of young founders whose wealth has surged due to high valuations in the private technology sector.The Times of IndiaEurope’s youngest self-made billionaire: James Dacombe dropped out of high school at 17 to build his startup and now his wealth has crossed the $1 billion mark at 25James Dacombe, a 25-year-old British entrepreneur, has become Europe’s youngest self-made billionaire after the valuation of his AI chip startup Olix surged following a $312 million funding round. Dacombe holds an estimated 30% stake in Olix, which is now valued at approximately $3.3 billion, while also maintaining a significant ownership position in his earlier venture, CoMind. This financial milestone places him among a small group of young tech founders who have achieved billionaire status through artificial intelligence developments.FortuneBillionaire Gen Zer dropped out of high school to launch his start-up at 17—now he’s Europe's richestJames Dacombe, a 25-year-old British entrepreneur, has become Europe's youngest self-made billionaire following a $312 million investment round that valued his AI chip company Olix at $3.3 billion. Dacombe also holds a significant stake in CoMind, another startup he founded, which recently raised $102.5 million. This event highlights the rapid accumulation of wealth among Gen Z founders in the artificial intelligence sector.BusinessCloudJames Dacombe profile: Meet the UK’s 25-year-old unicorn bossJames Dacombe, a 25-year-old sixth-form dropout from Harrogate, North Yorkshire, has founded two tech companies: AI chip company Olix, valued at $3.3bn after a $312m Series B raise, and neurotechnology firm CoMind, which secured £102.5m in a 2025 funding round led by Plural. Dacombe, a Thiel Fellow since 2022, launched Olix in 2024 to develop faster, cheaper and more energy-efficient inference chips designed specifically for AI workloads.Mpo-magAngelini Ventures Reinvests in CoMindAngelini Ventures has provided financial backing to the U.K. neurotechnology firm CoMind in a recent $60 million funding round, which CoMind has now raised a total of $102.5 million overall. This investment supports CoMind's efforts to gain U.S. regulatory approval for CoMind One, a non-invasive device designed to monitor key brain parameters. The investment signifies Angelini Ventures' strategic commitment to advancing brain health technologies.Healthcare TodayCoMind raises $60 million in Series A fundingLondon-based medical equipment manufacturer CoMind has raised $60 million in the second part of its Series A funding, led by Plural Platform. The funds will be used to advance regulatory approval for its CoMind One device and support clinical trials, team expansion, and manufacturing partnerships. This investment brings CoMind's total raised capital to $87 million as it works to develop non-invasive brain health monitoring technology.Med-Tech InsightsCoMind receives $100m+ funding for clinical brain monitoringCoMind raised $102.5 million to advance regulatory approval of its first product, CoMind One, a non-invasive device that continuously monitors cerebral blood flow, autoregulation, and intracranial pressure. The funding is led by Plural, with participation from LocalGlobe and Angelini Ventures. The company aims to use the data for future AI tools to guide treatment decisions.BenchCoMind Partners with Benchmark to Develop Groundbreaking Non-Invasive Brain Monitoring DeviceLondon-based medical technology startup CoMind has partnered with Benchmark, its development and manufacturing partner, to create a non-invasive brain monitoring device that uses low-powered infrared lasers to measure cerebral blood flow, intracranial pressure, and autoregulation. The device offers a safer alternative to traditional intracranial bolts, which require drilling into the skull and can lead to complications in up to 15 percent of cases, and has secured over $100 million in funding. With successful clinical trials completed in Barcelona and London, CoMind is now recruiting for its third US-based clinical trial to seek FDA approval.BebeezItaly’s angels & incubators and venture capital weekly roundup. News from CoMind, Angelini Ventures, Plural, LocalGlobe, Caracol, Ombes Capital, Move Capital Fund, CDP, Primo Capital, Eureka! Venture,This weekly roundup covers multiple Italian venture capital funding rounds and new fund launches, including neurotechnology startup CoMind raising $60 million led by Plural, 3D printing services provider Caracol securing 34.4 million euros from Omnes Capital, Move Capital Fund, CDP Venture Capital, and others, and deep-tech construction startup DMAT raising $4.5 million from Primo Capital and Safar Partners. CDP Venture Capital also launched Novagria Ventures, a 5.65 million euro venture building vehicle for the agrifood production chain targeting up to 6 new companies over three years. The remaining deals included Gevi (2.7M euros), TaDa (1.9M euros), and Poleepo (1M euros) in seed and early-stage rounds.